Top Story

Panobinostat regimen extended PFS in multiple myeloma

October 20, 2014

The addition of panobinostat to bortezomib and dexamethasone significantly extended PFS among patients with relapsed or relapsed/refractory multiple myeloma, according to results of the randomized phase 3 PANORAMA1 trial.

Preclinical studies showed panobinostat (LBH589, Novartis) — an oral pan-deacetylase inhibitor — has anti-myeloma activity when combined with bortezomib (Velcade, Millennium) and dexamethasone.

Institution Notes

Northwestern University cancer center appoints director

October 19, 2014
Leonidas Platanias, MD, PhD, has been appointed director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.Platanias, who served as interim…
figure Institution Notes

ASH elects four executive committee members

October 18, 2014
ASH elected four new members to its executive committee, the organization’s governing body.Kenneth C. Anderson, MD, will serve a 1-year term as vice president…
figure Meeting News Coverage

Targeted treatments for lung cancer likely to drive field forward

October 17, 2014
WASHINGTON — Recent progress in the use of genomics to treat lung cancer is likely to advance the field of cancer treatment, according to Mark G. Kris, MD
More News Headlines »

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video

Nomogram predicted recurrence risk among women who underwent APBI

September 26, 2014
Jessica Wobb, MD, senior resident in radiation oncology at Beaumont Health System in Birmingham, Mich., describes how…
More »

Treatment Decision-Making through the Spectrum of MDS: Case 2 High Risk MDS

An educational presentation from Aplastic Anemia & MDS International Foundation.

MDS is a difficult disease to diagnose and treat. Frequently it is challenging for healthcare providers to explain to…
More »